Concord Biotech gets EIR from USFDA for Gujarat facility

18 Aug 2023 Evaluate

Concord Biotech has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) indicating closure of inspection at its manufacturing Unit III, Gujarat. The company’s facility has been classified as ‘no action indicated’ (NAI). Based on this inspection and the USFDA NAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP). USFDA had conducted an inspection from June 26, 2023 to June 30, 2023.

Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.


Concord Biotech Share Price

1456.40 -9.15 (-0.62%)
07-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1507.00
Dr. Reddys Lab 6037.55
Cipla 1497.30
Zydus Lifesciences 1058.45
Lupin 1630.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.